Skip to content

ScienceLila Sciences

Lila Sciences

Autonomous AI labs pursuing scientific superintelligence.

Category
Science
Pricing
PAID
Hosting
Cloud
Platforms
Web
Verified
Jun 14, 2026

Lila Sciences is building a 'scientific superintelligence' platform that pairs a proprietary AI model with autonomous AI Science Factory lab instruments to generate hypotheses, design and run experiments, and learn in real time. It offers Catalyst, which augments existing R&D, and Creation, for new discoveries, across materials, therapeutics, chemicals, and energy. It is a platform and research company engaged through partnership rather than self-serve.

Pros & cons

  • Autonomous experiment loop
  • Cross-domain (materials to therapeutics)
  • Flagship Pioneering-backed
  • Deep funding (~$550M)
  • Partnership-only engagement
  • No public product or API
  • 'Superintelligence' claims unproven
  • Opaque pricing

Tags

Further reading

View all Science
  • View Isomorphic Labs details
    SciencePAID

    Isomorphic Labs

    Isomorphic Labs

    AI-first drug design built on AlphaFold for pharma R&D.

    Isomorphic Labs is an AI-first drug discovery company spun out of Google DeepMind, building generative and predictive ML models for molecular design and drug-performance prediction. Its Drug Design Engine builds on AlphaFold to advance internal and partnered pipelines with Eli Lilly, Novartis, and J&J. It is a drug-discovery company that works through pharma R&D partnerships rather than a self-serve product.

    Worth knowing

    DeepMind spinout (2021); raised a $600M Series A led by Thrive Capital with Alphabet and GV in March 2025 — its first external capital.

    • drug-discovery
    • alphafold
    • protein
    • biotech
  • View Cradle details
    SciencePAID

    Cradle

    Cradle

    AI protein-engineering platform for faster lab design rounds.

    Cradle is an AI-powered protein-engineering SaaS platform that guides scientists through design rounds — candidate generation, multi-property optimization, and results analysis — using ML models trained per-customer on proprietary wet-lab data. It runs its own validation wet lab in Amsterdam and serves biopharma and industrial-biotech R&D teams including Novo Nordisk and Johnson & Johnson. It is sold via subscription with no royalties, and customers keep full IP.

    Worth knowing

    Amsterdam-based; raised a $73M Series B led by IVP in Nov 2024, taking total funding past $100M, and runs its own validation wet lab.

    • protein-engineering
    • biotech
    • drug-discovery